<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="142352">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01247766</url>
  </required_header>
  <id_info>
    <org_study_id>IM101-213</org_study_id>
    <nct_id>NCT01247766</nct_id>
  </id_info>
  <brief_title>Safety Study of Abatacept to Treat Rheumatoid Arthritis</brief_title>
  <official_title>Post-marketing Observational Study Assessing the Long-term Safety of Abatacept Using a Population-based Cohort of Rheumatoid Arthritis Patients in the Province of British Columbia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Arthritis Research Centre of Canada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the incidence rates of infection, malignancy and
      death among patients with rheumatoid arthritis who are treated with abatacept and those who
      are treated with other anti-rheumatic medications for rheumatoid arthritis.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Anticipated">November 2018</completion_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Serious infection</measure>
    <time_frame>Every 2 years throughout the study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence rates of malignancy</measure>
    <time_frame>Every 2 years throughout the study</time_frame>
    <description>(total, lymphoma, lung cancer, breast cancer, colorectal cancer)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total mortality</measure>
    <time_frame>Every 2 years throughout the study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Multiple sclerosis</measure>
    <time_frame>Every 2 years throughout the study</time_frame>
    <description>To determine the incidence rate of multiple sclerosis (MS) in RA patients treated with abatacept and to compare this rate with the rate in RA patients matched for age, gender, RA duration and DMARD use, after adjusting for other potential confounders.</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">8000</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Patients with rheumatoid arthritis (RA) who receive abatacept</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with RA who receive BDM drugs</arm_group_label>
    <description>biologic disease-modifying (BDM)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with RA who receive non-biologic DMARDs</arm_group_label>
    <description>disease-modifying anti-rheumatic drugs (DMARDs)</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Residents of British Columbia who have received health care service for rheumatoid
        arthritis
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Rheumatoid arthritis

          -  Receipt of abatacept, other biologic disease-modifying drug, or any non- biologic
             disease-modifying anti-rheumatic drug

          -  Age 18 years or older

        Exclusion Criteria:

          -  Below 18 years of age
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/home.aspx</url>
    <description>BMS Clinical Trials Disclosure</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <link>
    <url>http://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>For FDA Safety Alerts and Recalls refer to the following link: http://www.fda.gov/MEDWATCH/safety.htm</description>
  </link>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 17, 2017</lastchanged_date>
  <firstreceived_date>November 23, 2010</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Abatacept</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
